Accessibility StatementSkip Navigation PITTSBURGH, Oct. 15, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced it has acquired Aculys Pharma, Inc., a clinical stage biopharmaceutical company focused on commercializing innovative treatments for neurological conditions. Viatris received rights to develop and commercialize pitolisant and Spydia, two assets in the Central Nervous System (CNS) therapy area, further expanding Viatris' portfolio of innovative products in ...

, /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that it has been named to Forbes' list of World's Best Employers 2025. This is the fifth year in a row that Viatris has received this recognition, which is presented by Forbes and Statista, the world-leading statistics portal and industry ranking provider. "Being included once again on the Forbes' World's Best Employers 2025 list is a great way to mark our company's upcoming fifth anniversary and a testament to our ...

Viatris (NASDAQ:VTRS) shares snapped six straight sessions of gains on Monday, as the stock closed 0.6% lower at $10.13. The healthcare gained 7% in the preceding six sessions. Overall, the stock has lost over 13% so far this year, compared to the 14% rise in the broader ...

Conservative Income Portfolio targets the best value stocks with the highest margins of safety. The volatility of these investments is further lowered using the best priced options. Our Enhanced Equity Income Solutions Portfolio is designed to reduce volatility while generating 7-9% yields.On our last coverage of Viatris Inc. (NASDAQ: VTRS ), we gave the complete record of the company's hits (less of these) and misses (way more of these). We also warned those trying to bottom fish at the first dayTrapping V ...

投资组合策略 - 保守收益投资组合旨在通过选择安全边际最高的优质价值股并运用定价最优的期权来降低投资波动性 [1] - 增强型股票收益解决方案投资组合的设计目标是在降低波动性的同时产生7%至9%的收益率 [1] - 备兑认购期权组合专注于资本保全并提供低波动性的收益投资 [1] - 固定收益投资组合专注于购买相对于可比证券被严重低估且具有高收益潜力的证券 [1] 分析团队背景 - Trapping Value是一个分析师团队在期权收益生成和资本保全方面拥有超过40年的综合经验 [2] - 该团队与Preferred Stock Trader合作运营保守收益投资组合 [2] - 该投资集团提供两个创收投资组合和一个债券阶梯 [2] 公司分析记录 - 对Viatris Inc的过往分析记录了该公司的业绩表现其中未达预期的情况远多于达到预期的情况 [1]

In this article, we will be taking a look at the 10 Best Pharma Stocks to Buy According to Billionaires. Viatris Inc. is one of them. Viatris Inc. (NASDAQ:VTRS), formed from the 2020 merger of Mylan and Pfizer’s Upjohn division, delivers essential generic and specialty medicines to patients in over 165 countries. The company maintains a broad portfolio across multiple therapeutic areas, focusing on sustainable growth, operational discipline, and shareholder returns. In September 2025, the corporation ach ...

Viatris (NASDAQ:VTRS) rose 2.93% on Wednesday to $9.84, breaking a sharp seven-session decline. Over the past seven trading days, VTRS shed around 9%, with daily losses including a 3.61% drop on September 15 and a 2.06% slide on September 12. The stock had been under ...

In this article, we will be taking a look at the 12 Cheap Healthcare Stocks to Buy Now. Viatris Inc. is one of them. Viatris Inc. (NASDAQ:VTRS), a global healthcare company formed from the 2020 merger of Mylan and Pfizer’s Upjohn division, continues to expand its presence in both generics and specialty pharmaceuticals. Operating in over 165 countries, the company blends established medicines with innovative therapies, positioning itself as a cost-effective healthcare stock backed by a growing late-stage p ...

行业表现与挑战 - 医疗保健行业在过去十年中仅在市场下跌时表现优于市场 但这种情况并非良好格局[2] - 大型制药业务表现受到一系列问题的显著影响[2] - 当前是医疗保健行业数十年来面临最大压力的时期 其中管理式医疗和制药领域承受最大市值负担[3] 选股方法论 - 筛选标准为市值超过20亿美元且远期市盈率低于15倍[5] - 从筛选池中选出前12只股票 并根据2025年9月10日的市盈率进行排名[5] 重点公司分析 - 博士健康公司(NYSE:BHC)远期市盈率1.45 通过收购DURECT获得具有FDA突破性疗法认定的larsucosterol 交易包含6300万美元首付款和最高3.5亿美元里程碑付款[7][8] - 公司肝病学产品组合得到加强 拥有针对酒精性肝炎的潜在首创疗法 预计覆盖美国每年16.4万住院病例[9] - 公司同时推进rifaximin SSD三期试验 预计2026年初公布顶线结果 并在医美领域推出Fraxel FTX激光设备[9] - Organon公司(NYSE:OGN)远期市盈率2.73 专注于女性健康、生物类似药和成熟药品[11] - 公司获得FDA对BILDYOS和BILPREVDA的批准 分别为PROLIA和XGEVA的生物类似药 旨在改善骨质疏松和骨癌治疗的可及性[12] - Viatris公司(NASDAQ:VTRS)远期市盈率4.40 由迈兰和辉瑞Upjohn部门合并而成[14] - 公司获得FDA对首款铁蔗糖注射剂仿制药的批准 原药Venofer在美国年销售额约5.15亿美元[15] - 公司报告多项管线资产取得积极后期试验结果 包括用于急性疼痛的快速作用美洛昔康和新一代避孕贴片XULANE LO[16]

股价技术表现 - 公司股价在周五交易中跌破200日移动平均线9.98美元 盘中最低触及9.95美元 [2] - 当日股价跌幅约1.9% 最新交易价格为9.96美元 [2] - 52周股价波动区间为6.85美元至13.55美元 当前价格接近区间下轨 [2] 市场数据来源 - 移动平均线数据来源于TechnicalAnalysisChannel.com [2] - 图表显示公司股价一年期表现与200日移动平均线对比关系 [2]